Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer

Advanced Non-squamous Non-small Cell Lung Cancer Clinical Trial

Official title:
A Prospective of Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer

Status Recruiting

Clinical Trial Summary

The purpose of this study is to explore the efficacy and safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint Inhibitors in Patients With Advanced Non-squamous Non-small Cell Lung Cancer

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Advanced Non-squamous Non-small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms

Clinical Trial Details

NCT number	NCT04137588
Study type	Observational [Patient Registry]
Source	Beijing Cancer Hospital
Contact	Jian Fang, doctor
Phone	+86-010-88196469
Email	bcht2_mj@163.com
Status	Recruiting
Phase
Start date	March 3, 2021
Completion date	June 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01063283` - Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC	N/A
Recruiting	`NCT05346952` - A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).	Phase 3
Completed	`NCT01204307` - Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation	Phase 2